Please wait a minute...
医药导报  2019, Vol. 38 Issue (6): 796-799    DOI: 10.3870/j.issn.1004-0781.2019.06.025
  本期目录 | 过刊浏览 | 高级检索 |
食物对小分子靶向药物生物利用度的影响
赵德华1(),楚明明2,陈静1,贾霖1,韩建军1,何霞1,龙小庆1,王继生1()
1.四川省绵阳市第三人民医院、四川省精神卫生中心临床药学科,绵阳 621000
2.陆军军医大学第二附属医院临床药学科,重庆 400037
全文: PDF(1211 KB)   HTML
输出: BibTeX | EndNote (RIS)      
摘要 

目的 探讨食物对小分子靶向药物体内生物利用度的影响。 方法 检索并整理食物影响小分子靶向药物生物利用度的相关文献,检索Pubmed、EMbase、Cochrane Library、中国知网、维普数据库、万方数据库。结果 食物可影响一部分小分子靶向药物的生物利用度,受到影响较为显著且具有临床意义的药物主要包括厄洛替尼、埃克替尼、拉帕替尼、尼洛替尼、凡德他尼、阿法替尼、依维莫司、索拉非尼、瑞戈非尼、色瑞替尼以及帕唑替尼 。结论 应重视食物与小分子靶向药物之间的相互作用,选择合理的服药时间,以避免增加药物不良反应或降低药物疗效。

服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵德华
楚明明
陈静
贾霖
韩建军
何霞
龙小庆
王继生
关键词 食物小分子靶向药物生物利用度药物不良反应    
收稿日期: 2018-01-15      出版日期: 2019-06-11
引用本文:   
赵德华,楚明明,陈静,贾霖,韩建军,何霞,龙小庆,王继生. 食物对小分子靶向药物生物利用度的影响[J]. 医药导报, 2019, 38(6): 796-799.
链接本文:  
http://www.yydbzz.com/CN/Y2019/V38/I6/796
[1] 张伯阳,许重远.肿瘤分子靶向治疗药物的研究与应用进展[J].中国临床药理学杂志,2015,31(12):1213-1217.
[2] 张师,王明霞,冯章英,等.靶向抗肿瘤药物的药动学相互作用研究进展[J].中国药房,2016,27(20):2871-2874.
doi: 10.6039/j.issn.1001-0408.2016.20.44
[3] 周虹,付国斌,张文,等.酪氨酸激酶抑制剂的药物相互作用研究进展[J].中国新药与临床杂志,2016,35(12):854-860.
[4] 陈晓媛,张虹,高晨燕,等.小分子靶向抗肿瘤药物临床研究策略探讨及案例分析[J].中国新药杂志,2013,22(3):269-273.
[5] GION P D,KANEFENDT F,LINDAUER A,et al.Clinical pharmacokinetics of tyrosine kinase inhibitors[J].Clin Pharmacok,2011,50(9):551-603.
doi: 10.2165/11587020-000000000-00000
[6] US Food and Drug Administration.Dasatinib(Sprycel)—Summary Basis of Approval(2006)[A].
[7] LOU Y,WANG L,QIAN Q,et al.Preclinical pharmaco-kinetics and tissue distribution of a novel multikinase inhibitor BZG by validated UPLC-MS/MS assay[J].J Pharm Biomed Anal,2016,121:107-113.
doi: 10.1016/j.jpba.2016.01.007
[8] PENG B,LLOYD P,SCHRAN H.Clinical pharmacokinetics of imatinib[J].Clin Pharmacokinet,2005,44(9):879-894.
doi: 10.2165/00003088-200544090-00001
[9] SWAISLAND H C,SMITH R P,LAIGHT A,et al.Single-dose clinical pharmacokinetic studies of gefitinib[J].Clin Pharmacokinet,2005,44(11):1165-1177.
doi: 10.2165/00003088-200544110-00004
[10] VISHWANATHAN K,DICKINSON P A,BUI K,et al.The Effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers[J].J Clin Pharmacol,2018,58(4):474-484.
doi: 10.1002/jcph.v58.4
[11] Food and Drug Administration.Product reviews and labels [EB/OL].(2016-10-04) [2016-10-10].http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
[12] SCHINDLER E,AMANTEA M A,KARLSSON M O,et al.A pharmacometric framework for axitinib exposure,efficacy and safety in metastatic renal cell carcinoma patients[J].CPT Pharmacometrics Syst Pharmacol,2017,6(6):373-382.
doi: 10.1002/psp4.v6.6
[13] YU M,GAO Z,DAI X,et al.Population pharmacokinetic and covariate Analysis of apatinib,an oral tyrosine kinase inhibitor,in healthy volunteers and patients with solid tumors[J].Clin Pharmacokinet,2016,56(1):65-76.
[14] BELLO C L,SHERMAN L,ZHOU J,et al.Effect of food on the pharmacokinetics of sunitinib malate(SU11248),a multi-targeted receptor tyrosine kinase inhibitor:results from a phase I study in healthy subjects[J].Anticancer Drugs,2006,17(3):353-358.
doi: 10.1097/00001813-200603000-00015
[15] SHUMAKER R,ALURI J,FAN J,et al.Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib(E7080) in healthy volunteers[J].Int J Clin Pharmacol Therap,2014,52(4):284-291.
doi: 10.5414/CP201937
[16] RUIZ-GARCIA A,MASTERS J C,MENDES DA COSTA L,et al.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers[J].J Clin Pharmacol,2016,56(2):223-230.
doi: 10.1002/jcph.v56.2
[17] LI C H,SHERER E A,LEWIS L D,et al.Clinical trial simulation to evaluate population pharmacokinetics and food effect:capturing abiraterone and nilotinib exposures[J].J Clin Pharmacol,2015,55(5):556-562.
doi: 10.1002/jcph.449 pmid: 25511575
[18] 程刚. 靶向治疗药物特罗凯的药代动力学优势[J].中国肺癌杂志,2009,12(6):619-622.
[19] LING J,FETTNER S,LUM B L,et al.Effect of food on the pharmacokinetics of erlotinib,an orally active epidermal growth factor receptor tyrosine-kinase inhibitor,in healthy individuals[J].Anticancer Drugs,2008,19(2):209-216.
doi: 10.1097/CAD.0b013e3282f2d8e4
[20] LIU D,JIANG J,ZHANG L,et al.Clinical pharmacokine-tics of icotinib,an anti- cancer drug:evaluation of dose proportionality,food effect,and tolerability in healthy subjects[J].Cancer Chemother Pharmacol,2014,73(4):721-727.
doi: 10.1007/s00280-014-2398-8
[21] MARTIN P,OLIVER S,KENNEDY S J,et al.Pharmaco-kinetics of vandetanib:three phase I studies in healthy subjects[J].Clin Therap,2012,34(1):221-237.
doi: 10.1016/j.clinthera.2011.11.011
[22] KOCH K M,REDDY N J,COHEN R B,et al.Effects of food on the relative bioavailability of lapatinib in cancer patients[J].J Clin Oncol,2009,27(8):1191-1196.
doi: 10.1200/JCO.2008.18.3285
[23] DEVRIESE L A,KOCH K M,MERGUI-ROELVINK M,et al.Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours[J].Investigational New Drugs,2014,32(3):481-488.
doi: 10.1007/s10637-013-0055-4
[24] YAP T A,VIDAL L,ADAM J,et al.Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors[J].J Clin Oncol,2010,28(25):3965-3972.
doi: 10.1200/JCO.2009.26.7278 pmid: 20679611
[25] CHEUNG W,LIGIA C,JAPPE A,et al.Pharmacokinetic(PK) profile of a single dose of everolimus(10 mg) administered with a low- or high-fat meal and under fasting conditions in healthy subjects[J].J Clin Oncol,2011,29(15):2696-2696.
doi: 10.1200/JCO.2010.33.7303
[26] KIM G M,KIM M D,KIM D Y,et al.Transarterial chemo-embolization using sorafenib in a rabbit VX2 liver tumor model:pharmacokinetics and antitumor effect[J].J Vasc Interv Radiol,2016,27(7):1086-1092.
doi: 10.1016/j.jvir.2016.02.032
[27] STRUMBERG D,RICHLY H,HILGER R A,et al.Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors[J].J Clin Ooncol,2005,23(5):965-972.
doi: 10.1200/JCO.2005.06.124
[28] GERISCH M,HAFNER F T,LANG D,et al.Mass balance,metabolic disposition,and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects[J].Cancer Chemother Pharmacol,2018,81(1):195-206.
doi: 10.1007/s00280-017-3480-9
[29] LAU Y Y,GU W,LIN T,et al.Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects[J].J Clin Pharmacol,2016,56(5):559-566.
doi: 10.1002/jcph.619
[30] WILLEMSEN A E,LUBBERMAN F J,TOL J,et al.Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors[J].Drug Discov Today,2016,21(6):962-976.
doi: 10.1016/j.drudis.2016.03.002
[31] VERHEIJEN R B,BEIJNEN J H,SCHELLENS J H,et al.Clinical pharmacokinetics and pharmacodynamics of pazopanib:towards optimized dosing[J].Clin Pharmacokinet,2017,56(9):987-997.
doi: 10.1007/s40262-017-0510-z
[1] 饶荣,杨祥良,刘卫. 多肽蛋白质药物口服纳米载药系统研究进展[J]. 医药导报, 2018, 37(6): 697-702.
[2] 刘蒸生,郝海军,马进安. 高乌甲素磷脂复合物及其固体分散体在大鼠体内的药动学[J]. 医药导报, 2018, 37(4): 449-452.
[3] 刘丹,于丽红,李磊. 提高白藜芦醇生物利用度的制剂策略*[J]. 医药导报, 2018, 37(3): 333-337.
[4] 李海春,王敏,谢鹏,祁静波,肖辉. 塞来昔布自微乳化释药系统的制备及体内外评价[J]. 医药导报, 2017, 36(5): 549-553.
[5] 叶伟红,应小飞,傅军霞,郭晶晶,徐艳艳,田伟强. 40例使用替加环素的临床用药分析*[J]. 医药导报, 2017, 36(1): 80-83.
[6] 付虹,邱召娟,戎有和. 静脉注射奈达铂注射液致严重不良反应1例[J]. 医药导报, 2016, 35(8): 901-902.
[7] 周莹,何晓梦,李虎群,倪扬,许明珍,黎维勇. 罗氟司特片在比格犬体内的药动学与相对生物利用度*[J]. 医药导报, 2016, 35(1): 4-4.
[8] 李杰,刘明周,黎维勇,贾萌萌,周颖,李虎群. 乙酰半胱氨酸颗粒在健康人体的生物等效性研究[J]. 医药导报, 2015, 34(8): 1014-1018.
[9] 李磊;王长远;蔡芸;高鹏程;田燕;刘克辛 . 羟丝肽口服微乳的制备与体内药动学研究[J]. , 2014, 33(2): 135-139.
[10] 舒成仁;卫乐乐. 盐酸西替利嗪咀嚼片生物等效性研究[J]. , 2012, 31(5): 588-591.
[11] 徐芳. 抗感染药物不良反应4 145例分析[J]. , 2012, 31(2): 261-263.
[12] 雷光远;雷招宝. 安乃近致死亡26例分析[J]. , 2012, 31(11): 1517-1521.
[13] 陈倩;刘宇;任秀华;张冬林;刘东. 佐匹克隆片人体相对生物利用度与生物等效性研究[J]. , 2012, 31(11): 1400-1403.
[14] 刘红梅;王智勇;赵红光;杜霞;董迪;宋笑丹;吴琳华. 奥美拉唑肠溶胶囊的人体相对生物利用度与生物等效性研究[J]. , 2011, 30(5): 584-586.
[15] 黄帮华. 我国医疗机构开展药物警戒工作的现状与建议[J]. , 2011, 30(3): 407-409.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   

通信地址:武汉市蔡甸区中法生态城同济医院专家社区C栋平层《医药导报》编辑部,邮政编码:430199
鄂ICP备07004419号
版权所有:《医药导报》编辑部
网址:www.yydb.cn;www.yydbzz.com
电话:027-69378382,69378383 电子邮箱: yydbzz@163.com
技术支持:北京玛格泰克科技发展有限公司 鄂ICP备09001709号-11